0001104659-21-098107.txt : 20210730 0001104659-21-098107.hdr.sgml : 20210730 20210730131514 ACCESSION NUMBER: 0001104659-21-098107 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20210730 FILED AS OF DATE: 20210730 DATE AS OF CHANGE: 20210730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zealand Pharma A/S CENTRAL INDEX KEY: 0001674988 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38178 FILM NUMBER: 211131547 BUSINESS ADDRESS: STREET 1: SMEDELAND 36 STREET 2: 2600 GLOSTRUP CITY: COPENHAGEN STATE: G7 ZIP: 00000 BUSINESS PHONE: 4588773600 MAIL ADDRESS: STREET 1: SMEDELAND 36 STREET 2: 2600 GLOSTRUP CITY: COPENHAGEN STATE: G7 ZIP: 00000 6-K 1 tm2122793d3_6k.htm FORM 6-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July 30, 2021

 

 

 

Commission File Number: 001 - 38178

 

 

 

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Sydmarken 11

2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ¨            Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S – Final Transactions Under Share Repurchase Program

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Zealand Pharma A/S
     
  By: /s/ Matthew Dallas
       
    Name: Matthew Dallas
    Title: Chief Financial Officer
       
Date: July 30, 2021      

 

2 

 

 

EXHIBIT INDEX

 

Exhibit
No.
  Description
     
99.1   Company announcement – No. 47 / 2021

 

3 

 

 

 

 

 

EX-99.1 2 tm2122793d3_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Company announcement – No. 47 / 2021 

 

 

Zealand Pharma A/S – Final Transactions Under Share Repurchase Program

 

 

Copenhagen, DK, 27 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016.

 

Zealand has entered an arrangement with Danske Bank A/S to act as exclusive manager under the program. Danske Bank A/S will buy back shares on behalf of Zealand and make related trading decisions independently of and without influence by Zealand.

 

Under the program, Danske Bank A/S will buy back shares on behalf of Zealand for an amount up to DKK 32,070,896. The share repurchase program is now completed. It was expected to be completed no later than July 29, 2021 and comprises up to 154,187 shares.

 

Since the announcement dated 20 July 2021, the following transactions have been made:

 

   Number of shares   Average price
 (DKK)
   Total value
(DKK)
 
Accumulated, last announcement   134,065    185,64    24,886,411 
20 July 2021   10,000    183,47    1,834,700 
21 July 2021   10,122    185,37    1,876,315 
Total   20,122    184.42    3,711,015 
Accumulated under the program   154,187    185,48    28,597,426 

 

The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

 

With the transactions stated above, Zealand owns a total of 218,410 shares with a nominal value of DKK 1 each as treasury shares, corresponding to 0.5% of the total share capital. The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.

 

# # #

 

About Zealand Pharma A/S


Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. In the United States Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes and Zegalogue® for the treatment of severe hypoglycemia in pediatric patients with diabetes aged 6 years and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

 

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

 

V-go® and Zegalouge® are registered trademarks of Zealand Pharma A/S

 

 

 

 

Forward-Looking Statement

 

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

 

For further information, please contact:

 

Zealand Pharma Investor Relations

Claudia Styslinger

Argot Partners
investors@zealandpharma.com

 

Zealand Pharma Media Relations

David Rosen

Argot Partners

media@zealandpharma.com


 

 

 

GRAPHIC 3 tn2122793d3_image001.jpg GRAPHIC begin 644 tn2122793d3_image001.jpg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